Resumen de acción 874
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, junto con sus filiales, investiga, desarrolla, fabrica y vende medicamentos chinos patentados y occidentales, materias primas químicas, medicamentos naturales y biológicos y productos intermedios de materias primas químicas en la República Popular China y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 4/6 |
| Dividendos | 3/6 |
Recompensas
Análisis de riesgos
Competidores de Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | HK$18.06 |
| Máximo en las últimas 52 semanas | HK$24.20 |
| Mínimo de 52 semanas | HK$16.62 |
| Beta | 0.59 |
| 1Cambio en 1 mes | -6.04% |
| Variación en 3 meses | -6.13% |
| Cambio de 1 año | -17.91% |
| 3Variación en 3 años | -5.54% |
| Variación en 5 años | -25.37% |
| Variación desde la OPV | 1,247.76% |
Noticias y actualizaciones recientes
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Recent updates
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 01Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models
Oct 29Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Oct 17Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Rentabilidad de los accionistas
| 874 | HK Healthcare | Mercado HK | |
|---|---|---|---|
| 7D | -0.6% | -0.2% | 1.6% |
| 1Y | -17.9% | -25.8% | 10.1% |
Rentabilidad vs. Industria: 874 superó a la industria Hong Kong Healthcare, que obtuvo un rendimiento del -25.8% el año pasado.
Rentabilidad vs. Mercado: 874 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fueron del 10.1% el año pasado.
Volatilidad de los precios
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 6.2% |
| Healthcare Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Precio estable de las acciones: 874 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 874 (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1997 | 28,760 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, junto con sus filiales, investiga, desarrolla, fabrica y vende medicamentos chinos patentados y occidentales, materias primas químicas, medicamentos naturales y biológicos y productos intermedios de materias primas químicas en la República Popular China y a escala internacional. La empresa opera a través de los segmentos Great Southern TCM, Great Commerce, Great Health y Otros. También se dedica a la venta al por mayor y al por menor, a la importación y exportación de medicamentos occidentales y chinos, instrumentos médicos, productos farmacéuticos, equipos médicos y productos sanitarios; a la investigación y desarrollo, producción y venta de bebidas, alimentos, productos sanitarios y otros productos; a la producción y venta de alimentos preenvasados, productos lácteos, etc., y ofrece infusiones, comprimidos, cápsulas, pastillas, gelatina de hierbas de tortuga, etc. Además, la empresa invierte en la industria sanitaria, como servicios médicos, gestión sanitaria, mantenimiento de la salud, cuidado de ancianos, etc.; y ofrece servicios de arrendamiento y comerciales, sanitarios, publicitarios, de descarga de carga y de almacén.
Resumen de fundamentos de Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
| Estadísticas fundamentales de 874 | |
|---|---|
| Capitalización bursátil | HK$47.66b |
| Beneficios(TTM) | HK$3.68b |
| Ingresos (TTM) | HK$82.11b |
8.0x
Ratio precio-beneficio (PE)0.4x
Ratio precio-ventas (PS)¿Está 874 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 874 | |
|---|---|
| Ingresos | CN¥76.39b |
| Coste de los ingresos | CN¥63.46b |
| Beneficio bruto | CN¥12.93b |
| Otros gastos | CN¥9.50b |
| Beneficios | CN¥3.42b |
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.11 |
| Margen bruto | 16.92% |
| Margen de beneficio neto | 4.48% |
| Ratio deuda/patrimonio | 35.5% |
¿Cómo se ha desempeñado 874 a largo plazo?
Ver rendimiento histórico y comparativa